The Metabolic Trifecta of Retatrutide

Retatrutide is a novel peptide drug that has been developed as a weight loss medication to target the receptors of three important metabolic hormones – glucagon-like peptide-1 (GLP-1), glucagon, and glucose-dependent insulinotropic peptide (GIP). This unique combination of actions make retatrutide a promising candidate for the treatment of type 2 diabetes and obesity, as it targets multiple pathways that regulate glucose metabolism, exergy expenditure, appetite, satiety and metabolism. In this blog post, we will explore the mechanisms of retatrutide as a GLP-1 agonist, glucagon agonist, and GIP agonist, and how these actions contribute to its extraordinary therapeutic potential.

GLP-1 Agonist Mechanism

GLP-1 agonists are a class of drugs that have been used to treat type 2 diabetes. Recently, they have gained attention for their potential use in weight management. The drugs work by mimicking the effects of the hormone glucagon-like peptide-1 (GLP-1), which is secreted by the intestines in response to food. GLP-1 stimulates insulin secretion, reduces glucagon secretion, and slows gastric emptying, which all contribute towards lowering blood glucose levels. In addition, GLP-1 increases feelings of satiety and reduces food consumption, leading to weight loss.

One of the key ways GLP-1 agonists help with weight loss is by reducing appetite. GLP-1 receptors are found in the brain, including the nucleus accumbens and hypothalamus, which play a critical role in reducing food (and alcohol) cravings, regulating appetite and improving energy balance. Activation of these receptors by GLP-1 agonists leads to a dramatic decrease in food intake, as well as increased feelings of fullness or satiety. This effect is thought to be mediated by the inhibition of neuropeptide Y (NPY) and agouti-related protein (AgRP) in the hypothalamus, which are known to stimulate appetite. GLP-1 agonists inhibit the activity of these neuropeptides, reducing feelings of hunger and increasing satiety.

Another way GLP-1 agonists help with weight loss is by slowing gastric emptying. When food enters the stomach, it is broken down before being passed into the small intestine for absorption. GLP-1 slows down the rate at which food leaves the stomach, which causes long lasting reductions in appetite following a meal. This effect is thought to be mediated by GLP-1 receptors in the stomach, which stimulate the release of gastric inhibitory polypeptide (GIP). GIP further slows the rate of gastric emptying, which in turn reduces food intake.

GLP-1 agonists also have the potential to increase thermogenesis and energy expenditure, which can contribute to weight loss. Studies have shown that GLP-1 agonists increase the basal metabolic rate and the amount of calories burned in a day. This effect is mediated by GLP-1 receptors in the brown adipose tissue, which are the metabolically active fat cells responsible for keeping the body warm and providing energy. In response to GLP-1 agonism, brown fat is stimulated to release norepinephrine, which ramps up the thermogenic fat burning process. GLP-1 agonists may also increase lean body mass, which can further contribute to increased energy expenditure.

Finally, GLP-1 agonists improve insulin sensitivity, which can help with weight loss. Insulin resistance is a common feature of obesity, and it can lead to hyperinsulinemia and weight gain. GLP-1 agonists improve insulin sensitivity in people with type 2 diabetes, which contributes to weight loss. This effect is thought to be mediated by GLP-1 receptors in the liver and skeletal muscle, which stimulate glucose uptake and glycogen synthesis.

Retatrutide exerts its GLP-1 agonist action by binding to and activating the GLP-1 receptor (GLP-1R), which is a G protein-coupled receptor expressed in various tissues, including pancreatic islets, gut, brain, and adipose tissue. Activation of GLP-1R by retatrutide leads to a cascade of intracellular signaling events that result in increased insulin secretion, decreased glucagon secretion, reduced food intake, increased energy expenditure and rapid weight loss. In addition, retatrutide enhances beta cell proliferation and survival, which may improve glucose homeostasis and prevent diabetes progression.

GIP Agonist Mechanism

Glucose-independent insulinotropic peptide, also known as Gastric Inhibitory Peptide or GIP, is a hormone secreted by the small intestine in response to food intake. It functions very similarly to GLP-1, working synergistically to promote healthy energy balance and metabolism. GIP stimulates the release of insulin from the pancreas in a glucose dependent manner, which helps to lower blood glucose levels. GIP agonists are drugs that mimic the effects of GIP and have an outstanding track record for promoting weight loss (tirzepatide). Here are some reasons why GIP agonists help with weight loss.

Firstly, GIP agonists reduce food intake. GIP receptors are found in the hypothalamus (similar to GLP-1). Activation of hypothalamic GIP receptors decreases food intake and increases satiety. This effect is further mediated by the release of peptide YY (PYY) and glucagon-like peptide-1 (GLP-1), which are known to stimulate satiety. GIP agonists synergistically stimulate the activity and release of these peptides, leading to reduced hunger and increased feelings of fullness.

Secondly, GIP agonists increase energy expenditure by stimulating the release of insulin in a glucose dependent manner. Improved insulin response promotes the uptake and utilization of glucose by muscle tissue. This can lead to increased energy expenditure and weight loss. GIP agonists mimic this effect, leading to increased glucose uptake and utilization by the body, brain and muscle. This leads to increased energy expenditure and weight loss.

Finally, GIP agonists may have a beneficial effect on gut microbiota and digestion. The importance of gut microbiota in energy metabolism and weight regulation cannot be understated and improvements in gut health can contribute greatly to long term weight loss success. GIP agonists have been shown to increase the abundance of beneficial gut bacteria, such as Bifidobacterium and Akkermansia, which are associated with improved metabolic health and weight loss.

Retatrutide acts as a GIP agonist by binding to and activating the GIP receptor (GIPR), which is a G protein-coupled receptor expressed in various tissues, including pancreatic islets, adipose tissue, and bone. Activation of GIPR by retatrutide leads to increased insulin secretion, enhanced glucose disposal, and lipolysis. GIP agonism may also have beneficial effects on bone metabolism and cardiovascular function, which are often compromised in patients with type 2 diabetes and obesity.

Glucagon Agonist Mechanism

Glucagon is a hormone that is secreted by the pancreas when blood glucose levels are low. It functions to elevate glucose to normal levels, so that the brain and body have the necessary energy to function. Glucagon agonists are a class of drugs that mimic the effects of glucagon and are being investigated for their potential use in weight loss. With this critical role in regulating blood glucose and metabolism, glucagon agonists have been shown to have potential as a target for weight management.

One of the key ways glucagon agonists help with weight loss is by increasing energy expenditure. Glucagon stimulates the breakdown of glycogen in the liver, which releases glucose into the bloodstream. This, in turn, stimulates the release of insulin, which promotes the uptake and utilization of glucose by the body. Glucagon agonists mimic this effect, leading to increased glucose uptake and utilization in muscle cells, which increases energy expenditure, weight loss and over -time can contribute to muscle hypertrophy.

Glucagon agonists also increase fat burning, which accelerates weight loss. Glucagon stimulates the breakdown of stored fat in adipose tissue, releasing fatty acids into the bloodstream. These fatty acids can then be used as a source of energy by the body’s cells. Glucagon agonists mimic this effect, leading to increased fat burning and weight loss.

Retatrutide acts as a glucagon agonist by binding to and activating the glucagon receptor (GCGR), which is also a G protein-coupled receptor expressed in the liver, pancreas, and brain. Activation of GCGR by retatrutide stimulates hepatic glucose production and lipolysis, which increases energy expenditure and improves insulin sensitivity. However, the potential adverse effects of glucagon stimulation, such as hyperglycemia and hyperglucagonemia, need to be carefully monitored and balanced with the glucose-lowering effects of GLP-1 and GIP agonism.

Conclusion

Retatrutide is a triple agonist for GLP-1, glucagon, and GIP receptors, which provides a unique spectrum of metabolic actions that are beneficial for the treatment of type 2 diabetes and obesity. Retatrutide’s GLP-1 agonism enhances insulin secretion, reduces food intake and reduces food cravings, while its glucagon agonism stimulates hepatic glucose production and energy expenditure, and its GIP agonism enhances glucose uptake, increase satiety and improves gut health. This combination of effects contributes to greatly accelerated fat loss effects when compared to other GLP-1 medications, while also decreasing the risk for side effects. However, retatrutide is not yet commercially available as an FDA approved medication. Retatrutide will likely be available for off label use in the next year, pending completion of the most recent stage 3 clinical trials.

Works Cited

1. 1. 1. Finan B, Clemmensen C, Müller TD, DiMarchi RD, Tschöp MH. Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists. Mol Metab. 2016;5(9):910-918. doi: 10.1016/j.molmet.2016.07.009
   1. 1. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 2016;24(1):15-30. doi: 10.1016/j.cmet.2016.06.009
   1. 1. Ali S, Ussher JR, Baggio LL, et al. Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction. Mol Metab. 2015;4(2):132-143. doi: 10.1016/j.molmet.2014.11.004
   1. 1. Killion EA, Wang J, Yie J, et al. Anti-diabetic effects of a triple GLP-1/GIP/glucagon receptor agonist in diet-induced obese mice. Am J Physiol Endocrinol Metab. 2013;305(5):E600-E611. doi: 10.1152/ajpendo.00037.2013
   1. 1. Finan B, Ma T, Ottaway N, et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Trans
   1. 1. Schmitz, S., Tchang, B.G. & Shukla, A.P. Obesity Pharmacotherapy: a Review of Current Practices and Future Directions. Curr Treat Options Gastro 21, 27–47 (2023). https://doi.org/10.1007/s11938-023-00409-1
   1. 1. Connor Enright, Elizabeth Thomas, David R Saxon, An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal, Journal of the Endocrine Society, Volume 7, Issue 3, March 2023, bvac195, https://doi.org/10.1210/jendso/bvac195
   1. 1. Juan Pablo Frías (2023) An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program, Expert Review of Endocrinology & Metabolism, 18:2, 111-130. https://www.tandfonline.com/doi/abs/10.1080/17446651.2023.2184796
   1. 1. Doggrell SA. Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 Apr 24:1-5. doi: 10.1080/13543784.2023.2206560. Epub ahead of print. PMID: 37086147.
   1. 1. Retatrutide by Eli Lilly and Co for Obesity: Likelihood of Approval. https://www.pharmaceutical-technology.com/data-insights/retatrutide-eli-lilly-and-co-obesity-likelihood-of-approval/
   1. 1. A Study of LY3437943 in Participants With Type 2 Diabetes. (Retatrutide Clinical Trials).
         https://clinicaltrials.gov/ct2/show/NCT04867785
   1. 1. Likelihood of Approval and Phase Transition Success Rate Model – Retatrutide in Obesity. https://www.globaldata.com/store/report/retatrutide-in-obesity-loa-and-ptsr-drug-analysis-393259/
   1. 1. Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon, A161, 2023, 170939, ISSN 0196-9781, https://doi.org/10.1016/j.peptides.2023.170939. (https://www.sciencedirect.com/science/article/pii/S0196978123000013)
   1. 1. Beylot, M., Previs, S. F., David, F., & Brunengraber, H. (1988). Determination of fat and glucose oxidation in vivo with stable isotopes. In Clinical Physiology of Exercise (pp. 95-106). Elsevier.
   1. 1. Cherrington, A. D., Liljenquist, J. E., Vranic, M., et al. (1979). Glucagon and insulin responses to alpha-adrenergic agents in man: studies with clonidine and yohimbine. The Journal of Clinical Endocrinology & Metabolism, 48(6), 965-970.
   1. 1. Kim, D., Wang, L., Beconi, M., Eiermann, G. J., Fisher, M. H., He, H., Hickey, G. J., Kowalchick, J. E., Leiting, B., Lyons, M. A., Marsilio, F., McCann, M. E., Patel, R. A., Petrov, A., Scapin, G., Patel, S. B., Roy, R. S., Wu, J. K., Wyvratt, M. J., Zhang, B. B., Zhu, L., Thornberry, N. A., & Weber, A. E. (2005). (2R)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Journal of Medicinal Chemistry, 48(9), 1416-1419.
   1. 1. Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003). The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes, 52(2), 380-386.
   1. 1. Nauck, M. A., Heimesaat, M. M., Behle, K., et al. (2002). Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. The Journal of Clinical Endocrinology & Metabolism, 87(3), 1239-1246.
   1. 1. Parkes, D. G., Pittner, R., Jodka, C., et al. (2011). LY315920/SNAC: a new glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism, 13(12), 1087-1094.
   1. Sandoval, D. A., & D’Alessio, D. A. (2015). Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiological Reviews, 95(2), 513-548.n update on peptide-based therapies for type 2 diabetes and obesity, Peptides.